Amgen highlights benefit of Prolia over Fosamax in fracture risk
JHVEPhoto

Real world data found that Amgen's (NASDAQ:AMGN) twice a year osteoporosis treatment Prolia (denosumab) led to greater decline in fraction risk over time compared to Fosamax (alendronate), which is given weekly.
A retrospective, observational study of ~479K postmenopausal women found that Prolia led to a 36% reduced risk of hip fractures. In addition, there was a 43% reduced risk of nonvertebral fractures and a 39% reduced risk of major osteoporotic, nonvertebral and hospitalized vertebral fractures.

In addition, Prolia reduced the risk of major osteoporotic fracture by 9% at year 1; 12% at year 2; 18% at year 3; and 31% at year 5.

More on Prolia

Amgen osteoporosis therapy linked to low blood calcium â FDA (update)
Novartis biosimilar matches Amgen's bone disorder drug Prolia, meeting trial's goal